Sibrafiban

Drugs

Volumn 57, Issue 2, 1999, Pages 225-230

  Dooley, Mukta ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PRODRUG; RO 443888; SIBRAFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART DISEASE; HEART INFARCTION; HUMAN; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; Q WAVE; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

ANIMALS; CLINICAL TRIALS; HUMANS; OXIMES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS;

EID: 0033043099     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00012     Document Type: Article

References (9)

1. Topol EJ, Califf R, Van de Werf F. Sibrafiban versus aspirin to yield maximum protection from ischaemic heart events post acute coronary syndromes (The SYMPHONY trial). Hoffmann- La Roche, clinical study protocol, 1997
2. Weller T, Alig L, Beresini M, et al. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39 (16): 3139-47
3. Alig L, Edenhofer A, Hadváry P, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-407
4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995 Jun 8; 332: 1553-9
5. Yun DD, Alpert JS. Acute coronary syndromes. Cardiology 1997; 88: 223-37
6. Refino CJ, Modi NB, Bullens S, et al. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost 1998 Jan; 79: 169-76
7. Modi NB, Lin YS, Reynolds T, et al. Pharmacokinetics and pharmacodynamics of Ro 48-3657, an orally active fibrinogen receptor antagonist, administered with heparin, aspirin and recombinant tissue-type plasminogen activator in beagles [abstract]. Pharm Res 1996 Sep; 13 Suppl.: 485
8. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998 Feb 3; 97: 340-9
9. F. Hoffman-La Roche Ltd. A randomised, double-blind, long-term, aspirin-controlled trial with two dosage regimens of sibrafiban (Ro 48-3657), an oral platelet glycoprotein IIb/IIIa antagonist, in patients following an Acute Coronary Syndrome. Clinical study protocol, 1998